Ayzsa Tannis

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024

Heidi L. Moline, Ayzsa Tannis, Ariana P. Toepfer et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 202 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

Risk Factors for Illness Severity Among Pregnant Women With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Infection—Surveillance for Emerging Threats to Mothers and Babies Network, 22 State, Local, and Territorial Health Departments, 29 March 2020–5 March 2021

Romeo R. Galang, Suzanne Newton, Kate R. Woodworth et al. · Clinical Infectious Diseases · 2021 · 115 citations · Full text

Public Health, Infectious Diseases, Maternal Health +17

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024

Heidi L. Moline, Ariana P. Toepfer, Ayzsa Tannis et al. · JAMA Pediatrics · 2024 · 61 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17

Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025

Monica E. Patton, Heidi L. Moline, Michael Whitaker et al. · MMWR Morbidity and Mortality Weekly Report · 2025 · 34 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

Substance Use Among Persons with Syphilis During Pregnancy — Arizona and Georgia, 2018–2021

Jeffrey M. Carlson, Ayzsa Tannis, Kate R. Woodworth et al. · MMWR Morbidity and Mortality Weekly Report · 2023 · 29 citations · Full text

Medicine, Maternal Health, Obstetrics +16